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ABSTRACT
Objective: Using probiotics in preventing ventilator-associated pneumonia (VAP) remain controversial due to different intensive care unit (ICU) 
populations included in such studies. The aim of this study is to evaluate the role of probiotics in prophylaxis of VAP after multiple trauma.
Methods: Sixty-five adult multiple trauma patients on mechanical ventilator (expected ≥48 h) after admission to the Critical Care Medicine 
Department, Alexandria Main University Hospital from June to November 2018. Patients were randomly assigned using computer sheet into two 
groups; probiotics group (32 patients received one Lacteol Forte® sachet through orogastric/nasogastric tube 3 times daily during their ICU stay) and 
control group (33 patients received similar regimen of placebo sachets). All patients were followed up and subjected to all possible strategies of the 
diagnosis of microbiologically confirmed VAP. 
Results: Sixty-five patients were enrolled with a mean of age (39.48±7.692) years, 80% of them were male. Regarding the incidence of VAP, it was 
18.46% of all patients without statistically significant difference between probiotics group (15.63%) and control group (21.21%) (p=0.751). 
Conclusion: Routine use of early probiotics in mechanically ventilated multiple trauma patients was not associated with lower incidence of VAP, 
duration of MV, or ICU mortality.
Trial Registration: Alexandria University, IRB No: 00007589 FWA No: 00015712
Keywords: Critical, Mechanical Ventilation, Pneumonia, Probiotics.
INTRODUCTION
Ventilator-associated pneumonia (VAP) is “a type of nosocomial 
pneumonia which occurs more than 48 h after intubation.” It is usually 
suspected when new or progressive infiltrate or clinical findings as 
fever ≥38°C, leukocytosis or leukopenia, and purulent secretions in 
contrast to hospital-acquired pneumonia, which occurs ≥ 48 h after 
admission without mechanical ventilation (MV) [1,2].
Globally, the prevalence of VAP is ranged between 10 and 20% of 
mechanically ventilated patients [3]. In recent research, the estimated 
overall mortality was about 13% [4]. Pseudomonas aeruginosa and 
Methicillin-resistant Staphylococcus aureus are the most prevalent 
organisms in VAP [5].Multiple factors are involved in the its pathogenesis 
including altered host immunity, oropharyngeal colonization, and 
factors associated with ventilator itself [2,6]. Although extensive 
studies for years, clear preventive strategies are still eluding VAP [7].
The World Health Organizations’ Food and Agriculture Organization 
defined probiotic as “live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host” [8]. Different 
probiotic species or combination appears effective in decreasing the 
risk of diarrhea due to clostridium difficile and other antibiotic-related 
diarrhea [9]. In two systematic reviews, prophylactic probiotics were found 
to reduce VAP but not mortality in intensive care unit (ICU) settings [10,11]. 
However, these two reviews were limited by clinical heterogeneity. These 
two reviews recommended that future studies should be conducted to find 
a benefit in trauma patients specifically [11,12].
The aim of this study is to evaluate the role of probiotics in VAP 
prophylaxis in critically ill patients after multiple trauma.
METHODS
After approval of the medical ethics committee of Alexandria Faculty of 
Medicine, an informed consent was taken from the patient’s next of kin. 
This study included 65 adult multiple trauma patients on mechanical 
ventilator (expected ≥48 h) who were admitted to the Critical Care 
Medicine Department, Alexandria Main University Hospital from June 
2018 to November 2018.
All enrolled patients were adults (˃18 years) mechanically ventilated 
with expected ventilation for ≥48 h with no evidence of pneumonia 
at admission and not receiving antibiotics (at least 5 days before). All 
patients with previous MV >12 h, enteral medication contraindications, 
pregnancy, history of bronchiectasis, cystic fibrosis, or witnessed 
pulmonary aspiration either prior or at intubation were excluded from 
the study.
Patients were examined at time of enrollment with complete 
history taking, physical examination, diagnosis, routine laboratory 
investigations, and chest X-ray. In this double blinded trial, patients were 
randomly assigned using computer sheet into two groups; probiotics 
group (32 patients received one Lacteol Forte® sachet through 
orogastric/nasogastric tube 3 times daily during their ICU stay) and 
control group (33 patients received similar regimen of placebo sachets). 
Lacteol Forte® sachet contains “Lactobacillus LB, corresponding to 
Lactobacillus delbrueckii and Lactobacillus fermentum (10 billion).”
All enrolled patients were followed up during their ICU stay. Protocol 
of treatment was not changed during the study time. The same VAP 
preventive strategy was used over the study time if no contraindication. 
This strategy includes bed elevation, oral care, sedation interruption, 
stress ulcer, and deep vein thrombosis prophylaxis. Primary outcome 
was the diagnosis of VAP (using clinical, invasive diagnostic strategy, 
and surveillance for ventilator-associated events). Secondary outcomes 
were MV days and all cause in ICU mortality.
Statistical analysis of the data [13]
Data were fed to the computer and analyzed using IBM SPSS software 
package version 24.0 [14]. Qualitative data were described using 
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number and percent. Quantitative data were described using mean, 
standard deviation, and median. Significance of the obtained results 
was judged at the 5% level. Chi-square test was used for categorical 
variables to compare between different groups. Fisher’s exact or Monte 
Carlo correction was a correction for Chi-square when applicable. 
Student’s t-test was used for normally quantitative variables. Mann–
Whitney U-test was used for abnormally quantitative variables. 
RESULTS
In this study, two studied groups (probiotic and control) were studied. 
The mean of age of all patients was 39.48±7.692 years. About 80% of 
participants were males. There were no statistically significant differences 
between the two studied groups in their age (p=0.918) or sex (p=0.367).
At initial assessment, both groups were presented with nearly similar 
hemodynamics. There were no statistically significant differences 
between them in their mean arterial pressure (p=0.869), heart rate 
(p=0.610), temperature (p=0.162), or respiratory rate (p=0.224).
Regarding inflammatory markers, there were no statistically significant 
differences between them in their levels of C-reactive protein (p=0.156), 
procalcitonin (p=0.171), or white blood cells count (p=0.553) (Table 1).
Regarding the main study outcome (the incidence of VAP), it was 
18.46% of all enrolled patients during their ICU stay. It was lower in 
probiotic group (15.63%) than control group (21.21%) but without 
statistically significant difference (p=0.751) (Fig. 1). Regarding the 
secondary outcomes, there were no statistically significant differences 
between the two groups in their duration of MV (p=0.182) or ICU 
mortality (p=1.000) (Table 2).
DISCUSSION
In this study, the incidence of VAP was investigated during ICU stay of 
two comparable groups of patients (n=65) after multiple trauma on MV. 
It was found to be 18.46%. Using prophylactic probiotic early (15.63%) 
was not associated with lower incidence than placebo (21.21%) 
(p=0.751) or different outcomes as duration of MV (p=0.182) and ICU 
mortality (p=1.000).
In contrast, Gu et al. meta-analysis of five randomized controlled 
trials (RCTs) showed that probiotics were associated with lower 
incidence of nosocomial infections by 35% generally. Specifically, it 
was associated with lower VAP and ICU stay with no difference in 
mortality [12].
Furthermore, Bo et al. meta-analysis showed that there is no enough 
evidence to draw conclusions on the efficacy of routine use of probiotics 
to decrease incidence of VAP or mortality in ICU patients. However, only 
Table 1: Baseline characteristics of all enrolled patients
Overall (n=65) Probiotic group (n=32) Control group (n=33) p value
No. % No. % No. %
Male 52 80 24 75 28 84.8 0.367
Female 13 20 8 25 5 15.2
Age (years) 39.48±7.692 39.08±7.113 39.88±7.905 0.918
MAP (mmHg) 85.62±9.846 86.40±12.644 84.83±8.979 0.869
HR (beats/min) 102.74±14.127 103.66±14.779 101.85±13.634 0.610
Temp. (ºC) 37.04±0.134 37.06±0.168 37.02±0.087 0.162
RR (breaths/min) 25.71±4.537 26.41±4.771 25.03±4.261 0.224
WBCs×109/L 9.83±1.620 9.95±1.618 9.71±1.639 0.553
CRP (mg/L) 18.4±10.058 16.59±10.014 20.15±9.937 0.156
PCT (ng/mL) 0.34±0.131 0.32±0.132 0.36±0.129 0.171
GCS 9.11±1.134 9.06±1.162 9.15±1.121 0.754
MAP: Mean arterial pressure, HR: Heart rate, RR: Respiratory rate, Temp: Surface body temperature, GCS: Glasgow Coma Scale. *p value is significant when p≤0.05. Data 
are expressed as number, % or mean ±S.D.
Table 2: The measured outcomes of all enrolled patients
Overall (n=65) Probiotic group (n=32) Control group (n=33) p value
No. % No. % No. %





































Duration of MV (days) 9.46±3.845 11.60±4.775 9.10±3.642 0.182
ICU LOS (days) 12.91±3.838 14.60±4.775 12.63±3.681 0.296
ICU mortality 23 35.38 11 34.38 12 36.36 1.000
MRSA: Methicillin-resistant Staphylococcus aureus. *p value is significant when p≤0.05. VAP: Ventilator-associated pneumonia, ICU: Intensive care 
unit.   Data are expressed as number, % or mean ±S.D.
Fig. 1: The incidence of ventilator-associated pneumonia of the 
two studied groups
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one study showed that there was a strong justification for the use of 
probiotics in trauma patients[11].
In all included studies, different compositions of probiotics were tested. 
For example, a synbiotics formulation which contains Pediococcus 
pentosaceus, Leuconostoc mesenteroides, Lactobacillus paracasei sp., and 
Lactobacillus plantarum was associated with similar incidence of VAP 
(9%) when compared to placebo (13%) [15]. While, another contain 
only Lactobacillus rhamnosus was associated with lower incidence 
(19%) versus placebo (40%) [16].
To the best of our knowledge, this was the first RCT to investigate 
the role of probiotics in multiple trauma patients after the previously 
mentioned two reviews. We think that there are many confounding 
factors incorporated in these conflicting results other than mixed 
populations included, different formulations of prebiotics, probiotics, 
and synbiotics, no standard content in these products was used, 
different preventive strategies and bundles for VAP and lack of evidence 
supporting the use of these formulations in nasogastric and orogastric 
tubes. All these limitations can be applied to our study besides its small 
sample size. 
CONCLUSION
From the results of this study, routine use of early probiotics in 
mechanically ventilated multiple trauma patients was not associated 
with lower incidence of VAP, duration of MV, or ICU mortality. After 
controlling confounding factors, further larger multicentric studies are 
required to verify these results. 
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